Renee Tannenbaum

Renee P. Tannenbaum, PharmD, BSc, MBA is a pharmaceutical executive with over 40 years of successful operating and general management experience. Dr. Tannenbaum previously served as the vice president of global partnering at Halozyme, Inc., where she was responsible for leading business development activities and the company’s alliances through partnerships and collaborations. Prior to her time at Halozyme, Dr. Tannenbaum served as the head of global customer excellence at AbbVie, where she was responsible for building commercial capabilities for the organization, president of Myrtle Potter & Company, LLC, a global life-sciences consulting and advisory firm, and executive vice president and chief commercial officer at Elan Pharmaceuticals, Inc.

During her time at Elan, Dr. Tannenbaum was responsible for revenue generation from Elan’s marketed products, preparing for the commercialization of pipeline candidates, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum spent three years leading the global commercial operations organization at Novartis Pharma AG, and nine and sixteen years at Bristol Myers Squibb and at Merck and Company, Inc., respectively, where she held a variety of leadership positions in operations and general management.

She has extensive Board experience, as she is currently a director at ANI Pharmaceuticals and Cardiff Oncology. Previously she served as a director at both public and private companies, including, Zogenix, Inc., Nordic Nanovector ASA, Cipher Pharmaceuticals, Inc., Sharps Compliance Inc., and Immune Pharmaceuticals, Inc. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her B.Sc. in Pharmacy from the University of Connecticut.